Last reviewed · How we verify

NCT05651685

Treatment Recommendations for Patients With ADHD TDApp2

Completed Last updated 1 July 2024
What this trial tests

trial in Attention Deficit Disorder With Hyperactivity in 32 participants. Completed in 28 June 2024.

Timeline
12 December 2022
Primary endpoint
28 June 2024
28 June 2024

Quick facts

Lead sponsorUniversitat de Girona
StatusCompleted
Study typeOBSERVATIONAL
Enrollment32
Start date12 December 2022
Primary completion28 June 2024
Estimated completion28 June 2024
Sites1 location across Spain

Conditions studied

Sponsor

Universitat de Girona

Who can join

Adults 6 to 17, any sex, with Attention Deficit Disorder With Hyperactivity. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

The purpose of this study is to compare the recommendations made by TDApp2 with those by relevant clinical practice guidelines in children/adolescents with ADHD.

Publications & conference data

1 peer-reviewed publication reference this trial (live from Europe PMC):

  1. Assessing TDApp: An AI-based clinical decision support system for ADHD treatment recommendations.
    Baykova E, Raya Ò, Lombardía C, Gonzalvo B, et al · · 2025 · cited 1× · PMID 40917247 · DOI 10.3389/fpsyt.2025.1582746

Verify or expand the search:

Other recruiting trials for Attention Deficit Disorder With Hyperactivity

Currently open trials in the same condition.

Other Universitat de Girona trials

Trials by the same sponsor.

Verify against primary sources

Data sources for this page

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05651685.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing